These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23828409)

  • 41. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
    Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
    Wang H; Dai YY; Zhang WQ; Hsu PC; Yang YL; Wang YC; Chan G; Au A; Xu ZD; Jiang SJ; Wang W; Jablons DM; You L
    Int J Oncol; 2017 Jul; 51(1):91-103. PubMed ID: 28560410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
    Schramm A; Opitz I; Thies S; Seifert B; Moch H; Weder W; Soltermann A
    Eur J Cardiothorac Surg; 2010 Mar; 37(3):566-72. PubMed ID: 19781955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
    Liu H; Wu L; Ji K; Wang W
    Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
    Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.
    Righi L; Cavallo MC; Gatti G; Monica V; Rapa I; Busso S; Albera C; Volante M; Scagliotti GV; Papotti M
    Am J Clin Pathol; 2014 Jun; 141(6):816-27. PubMed ID: 24838326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.
    Pillai K; Pourgholami MH; Chua TC; Morris DL
    Am J Cancer Res; 2013; 3(4):411-23. PubMed ID: 23977450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.
    Pillai K; Pourgholami MH; Chua TC; Morris DL
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):987-94. PubMed ID: 23463097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.
    Creaney J; Segal A; Sterrett G; Platten MA; Baker E; Murch AR; Nowak AK; Robinson BW; Millward MJ
    Br J Cancer; 2008 May; 98(9):1562-9. PubMed ID: 18454162
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Paajanen J; Laaksonen S; Ilonen I; Wolff H; Husgafvel-Pursiainen K; Kuosma E; Ollila H; Myllärniemi M; Vehmas T
    Lung Cancer; 2018 Feb; 116():73-79. PubMed ID: 29413055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
    Duyar SŞ; Yilmaz A; Demirag F; Erdoğan Y; Yazici Ü; Karakaya J
    Turk J Med Sci; 2015; 45(3):607-14. PubMed ID: 26281327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.
    Bozzi F; Brich S; Dagrada GP; Negri T; Conca E; Cortelazzi B; Belfiore A; Perrone F; Gualeni AV; Gloghini A; Cabras A; Brenca M; Maestro R; Zaffaroni N; Casali P; Bertulli R; Deraco M; Pilotti S
    Oncotarget; 2016 Nov; 7(46):75503-75517. PubMed ID: 27705913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
    Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P
    Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
    Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C
    Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.